GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ASKA Pharmaceutical Holdings Co Ltd (TSE:4886) » Definitions » Change In Receivables

ASKA Pharmaceutical Holdings Co (TSE:4886) Change In Receivables : 円0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is ASKA Pharmaceutical Holdings Co Change In Receivables?

ASKA Pharmaceutical Holdings Co's change in receivables for the quarter that ended in Dec. 2023 was 円0 Mil. It means ASKA Pharmaceutical Holdings Co's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

ASKA Pharmaceutical Holdings Co's change in receivables for the fiscal year that ended in Mar. 2024 was 円-370 Mil. It means ASKA Pharmaceutical Holdings Co's Accounts Receivable increased by 円370 Mil from Mar. 2023 to Mar. 2024 .

ASKA Pharmaceutical Holdings Co's Accounts Receivable for the quarter that ended in Dec. 2023 was 円18,307 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ASKA Pharmaceutical Holdings Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 97.26.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ASKA Pharmaceutical Holdings Co's liquidation value for the three months ended in Dec. 2023 was 円9,474 Mil.


ASKA Pharmaceutical Holdings Co Change In Receivables Historical Data

The historical data trend for ASKA Pharmaceutical Holdings Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASKA Pharmaceutical Holdings Co Change In Receivables Chart

ASKA Pharmaceutical Holdings Co Annual Data
Trend Mar22 Mar23 Mar24
Change In Receivables
-1,361.00 -742.00 -370.00

ASKA Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ASKA Pharmaceutical Holdings Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASKA Pharmaceutical Holdings Co  (TSE:4886) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ASKA Pharmaceutical Holdings Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=18307/17176*91
=97.26

2. In Ben Graham's calculation of liquidation value, ASKA Pharmaceutical Holdings Co's accounts receivable are only considered to be worth 75% of book value:

ASKA Pharmaceutical Holdings Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=20354-34467+0.75 * 18307+0.5 * 19713
=9,474

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASKA Pharmaceutical Holdings Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description

Traded in Other Exchanges
N/A
Address
2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and related operations.

ASKA Pharmaceutical Holdings Co (TSE:4886) Headlines

No Headlines